doi:10.1016/j.jhep.2010.08.036
Glucagon-like peptide-1 (GLP-1) has emerged as a therapeutic agent for metabolic diseases such as obesity, NAFLD, and atherosclerosis, largely by improving lipid, glucose, and cholesterol metabolism [15]
Hgb 9.8 g/dL (down from 11.2 six months ago), ferritin 11 ng/mL, TSAT 9%
GLP-1 medications (semaglutide, tirzepatide, etc.) have helped many people reach healthier weights, but relying on them indefinitely can come with trade-offs: loss of muscle, facial volume changes (the so-called Ozempic face), sagging or loss of gluteal fullness, and difficulty maintaining tone when meds are reduced or stopped
Even if you were on 2 } Tips for a Smooth Transition Small adjustments to your routine can make a big difference during the switch
Rev.2000,100, 909-911 50